Scholarlink

<p>Current guidelines do not routinely recommend PET-CT for staging early breast cancer (EBC). This study evaluates PET-CT as a single-modality tool for detecting occult metastases in EBC, stratified by molecular subtypes.&#xa0;A prospective cohort study of 151 biopsy-proven EBC patients (cT1-T2 NO-N1, cT3-N0) underwent staging PET-CT. Patients were stratified into LOW-RISK (HR+/HER2−; <i>n</i> = 88) and HIGH-RISK (TNBC/HER2+; <i>n</i> = 63) groups. The primary endpoint was PET-CT-driven treatment modification. Statistical analysis used chi-square tests (SPSS v28).&#xa0;PET-CT altered management in 24/151 patients (15.89%). Findings included distant metastases (bone: 2.6%, lung nodules: 1.32%), extra-axillary nodal involvement (internal mammary: 3.31%, contralateral axillary: 1.32%), and synchronous malignancies (endometrial: 2.6%, ovarian/renal/contralateral breast: 0.6% each). High-risk subtypes had significantly higher PET-CT-detected events (17/63; 11.2%) versus low-risk (7/88; 4.6%) (<i>p</i> = 0.0034).&#xa0;PET-CT in EBC upstaged disease or revealed synchronous malignancies in 15.89% prompting modification of treatment. High risk (TNBC/HER2+) molecular subtypes demonstrated significantly greater benefit, supporting PET-CT use in EBC despite guideline limitations while the Low risk (HR +/HER2 - ) molecular types can be staged in the conventional way.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PET-CT for Staging in Early Breast Carcinoma: Insights from our Institute Experience - a Prospective Cohort Study

  • 期刊论文

  • 发表日期：

    2025年7月1日

查看全文
  • D. Suresh Kumar,
  • Navin Noushad,
  • M. P. Vishwanathan,
  • K. Senthil Kumar

摘要

Current guidelines do not routinely recommend PET-CT for staging early breast cancer (EBC). This study evaluates PET-CT as a single-modality tool for detecting occult metastases in EBC, stratified by molecular subtypes. A prospective cohort study of 151 biopsy-proven EBC patients (cT1-T2 NO-N1, cT3-N0) underwent staging PET-CT. Patients were stratified into LOW-RISK (HR+/HER2−; n = 88) and HIGH-RISK (TNBC/HER2+; n = 63) groups. The primary endpoint was PET-CT-driven treatment modification. Statistical analysis used chi-square tests (SPSS v28). PET-CT altered management in 24/151 patients (15.89%). Findings included distant metastases (bone: 2.6%, lung nodules: 1.32%), extra-axillary nodal involvement (internal mammary: 3.31%, contralateral axillary: 1.32%), and synchronous malignancies (endometrial: 2.6%, ovarian/renal/contralateral breast: 0.6% each). High-risk subtypes had significantly higher PET-CT-detected events (17/63; 11.2%) versus low-risk (7/88; 4.6%) (p = 0.0034). PET-CT in EBC upstaged disease or revealed synchronous malignancies in 15.89% prompting modification of treatment. High risk (TNBC/HER2+) molecular subtypes demonstrated significantly greater benefit, supporting PET-CT use in EBC despite guideline limitations while the Low risk (HR +/HER2 - ) molecular types can be staged in the conventional way.